Targeting the NF-κB pathway for therapy of ischemic stroke

Ther Deliv. 2020 Feb;11(2):113-123. doi: 10.4155/tde-2019-0075. Epub 2020 Jan 13.

Abstract

Ischemic strokes occur when a major cerebral artery or its branches are occluded, resulting in activation of inflammatory processes that cause secondary tissue injury, breakdown of the blood-brain barrier, edema or hemorrhage. Treatments that inhibit inflammatory processes may thus be highly beneficial. A key regulator of the inflammatory process is the nuclear factor kappa B (NF-κB) pathway. In its active form, NF-κB regulates expression of proinflammatory and proapoptotic genes. The molecules that interact with NF-κB, and the subunits that compose NF-κB itself, represent therapeutic targets that can be modulated to decrease inflammation. This review focuses on our current understanding of the NF-κB pathway and the potential benefits of inhibiting NF-κB in ischemia-reperfusion injury of the brain.

Keywords: inflammation; ischemic stroke; nuclear factor κB (NF-κB).

Publication types

  • Review

MeSH terms

  • Brain Ischemia* / drug therapy
  • Humans
  • Ischemic Stroke*
  • NF-kappa B
  • Reperfusion Injury* / drug therapy
  • Stroke* / drug therapy

Substances

  • NF-kappa B